SINGAPORE, Aug. 18, 2025 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a clinical-stage biopharmaceutical firm based in Singapore, is pleased to announce it has entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (the “Agent”), acting as the sales agent. CytoMed focuses on using its technologies to create allogeneic cell-based therapies from donor blood for treating blood cancers and solid tumors affordably.

As per the Sales Agreement, the Company may offer and sell ordinary shares (“Shares”) through the Agent, with a total value of up to U.S.$4,304,945. The Company will decide the timing and amount of Share sales under the ATM program at its discretion, based on market conditions and its capital needs.

The Company plans to use the ATM program’s proceeds for general corporate purposes, potentially including business diversification, development projects, and capital expenditures. A portion of the proceeds may also be used to hire professionals to explore potential acquisitions or strategic investments in related businesses or technologies. However, as of this press release, the Company has not entered into any definitive agreements. The Company will update shareholders as more information is available. Any net proceeds not immediately used may be temporarily held as cash or deposited in banks. The company’s recently acquired cord blood bank has seen approximately 2,500 new customer sign-ups since August 2024, contributing to revenue in 2025.

About CytoMed Therapeutics Limited (CytoMed)

CytoMed, established in 2018, originated from the Agency for Science, Technology and Research (A*STAR), Singapore’s main public sector R&D agency. CytoMed is a clinical-stage biopharmaceutical company dedicated to leveraging its licensed technologies, specifically gamma delta T cells and iPSC-derived gamma delta Natural Killer T cells, to develop innovative allogeneic cell-based immunotherapies for treating various human cancers. The development of new technologies has been fueled by the clinical success of CAR-T therapies in treating blood cancers, as well as the current clinical limitations and commercial challenges in applying the CAR-T principle to solid tumor treatment. For further details, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements involve plans, objectives, goals, strategies, future events or performance, and underlying assumptions, as well as other statements that are not strictly historical facts. The use of terms like “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not solely relate to historical matters indicates forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ materially from the Company’s expectations expressed in these statements. These risks and uncertainties include, but are not limited to: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress, and results of the Company’s current and future pre-clinical studies and clinical trials, and its R&D programs; the Company’s estimates of expenses, future revenue, capital requirements, and the need for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding, and assumptions related to any of the foregoing, as well as other risks detailed in the Company’s filings with the SEC. Investors are therefore cautioned against placing undue reliance on any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, available at www.sec.gov. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances that occur after the date of this release.

Contact :

CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer